According to filings with the U.S. Securities and Exchange Commission, Invectys is raising up to $4,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Jake Kushner played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Invectys
Invectys, Inc. is a privately owned clinical-stage company, headquartered in Houston, Texas, which is developing a new generation of First-in-Class products for cancer patients. Invectys has two wholly owned subsidiaries, Invectys, SAS (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston) which is directing the clinical development of the Companys lead HLA-G product. Since 2010, Invectys has raised over $60 million in private funds to develop its two innovative platforms of immunotherapy products which target universal tumor antigens.

To learn more about Invectys, visit http://www.invectys.com/
Invectys Linkedin Page: https://www.linkedin.com/company/invectys/

Contact:
Jake Kushner, Chief Executive Officer
585-278-3001

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.